Targeting replication stress in cancer therapy
Replication stress is a major cause of genomic instability and a crucial vulnerability of
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
cancer cells. This vulnerability can be therapeutically targeted by inhibiting kinases that …
Clinical and translational advances in ovarian cancer therapy
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …
is initially very responsive to platinum-based chemotherapy. However, the majority of …
[HTML][HTML] Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer
L Yang, HJ **e, YY Li, X Wang, XX Liu… - Oncology …, 2022 - spandidos-publications.com
Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in …
Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids
Based on genomic analysis, 50% of high-grade serous ovarian cancers (HGSC) are
predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually …
predicted to have DNA repair defects. Whether this substantial subset of HGSCs actually …
The Fanconi anemia pathway in cancer
Fanconi anemia (FA) is a complex genetic disorder characterized by bone marrow failure
(BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer …
(BMF), congenital defects, inability to repair DNA interstrand cross-links (ICLs), and cancer …
Biomarker-guided development of DNA repair inhibitors
JM Cleary, AJ Aguirre, GI Shapiro, AD D'Andrea - Molecular cell, 2020 - cell.com
Anti-cancer drugs targeting the DNA damage response (DDR) exploit genetic or functional
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
defects in this pathway through synthetic lethal mechanisms. For example, defects in …
Overcoming platinum and PARP-inhibitor resistance in ovarian cancer
M McMullen, K Karakasis, A Madariaga, AM Oza - Cancers, 2020 - mdpi.com
Platinum chemotherapy remains the cornerstone of treatment for epithelial ovarian cancer
(OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as …
(OC) and Poly (ADP-ribose) polymerase inhibitors (PARPi) now have an established role as …
Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor–resistant cancer
N Gupta, TT Huang, S Horibata, JM Lee - Pharmacological research, 2022 - Elsevier
Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) have become a
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
mainstay of therapy in ovarian cancer and other malignancies, including BRCA-mutant …
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy
Despite advances in immuno-oncology, the relationship between tumor genotypes and
response to immunotherapy remains poorly understood, particularly in high-grade serous …
response to immunotherapy remains poorly understood, particularly in high-grade serous …
Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors
KT Do, B Kochupurakkal, S Kelland, A de Jonge… - Clinical Cancer …, 2021 - AACR
Abstract Purpose: Checkpoint kinase 1 (CHK1) plays a central role in the response to
replication stress through modulation of cell-cycle checkpoints and homologous …
replication stress through modulation of cell-cycle checkpoints and homologous …